2019
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes
Zeidan AM, Klink AJ, McGuire M, Feinberg B. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Leukemia & Lymphoma 2019, 60: 2050-2055. PMID: 30636526, DOI: 10.1080/10428194.2018.1551538.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeFirst-line useLonger treatment durationAgent azacitidineTreatment discontinuationClinical outcomesMedian timeInsurance disenrollmentUS payersTreatment durationLenalidomidePatientsTreatment sequenceOptimal sequencingSyndromeSurvivalOutcomesDiscontinuationAzacitidineDecitabineDisenrollment
2018
Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?
Shallis RM, Zeidan AM. Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty? Leukemia & Lymphoma 2018, 59: 2015-2017. PMID: 29411698, DOI: 10.1080/10428194.2018.1430797.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2017
Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome
Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Annals Of Hematology 2017, 96: 1037-1039. PMID: 28220192, DOI: 10.1007/s00277-017-2954-5.Peer-Reviewed Case Reports and Technical NotesLenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications
Stahl M, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer 2017, 123: 1703-1713. PMID: 28192601, DOI: 10.1002/cncr.30585.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaProlong survivalLow-risk MDSLR-MDS patientsEfficacy of lenalidomideImpressive clinical activityRecent clinical dataClonal myeloid neoplasmsMechanism of actionBlood cytopeniasConventional careTransfusion independenceCytogenetic responseClinical activityMyeloid leukemiaClinical dataIneffective hematopoiesisMyeloid neoplasmsDelay progressionHigh riskLenalidomidePatientsVariable riskHeterogeneous groupProgression
2016
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher‐risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia
Zeidan AM, Smith BD, Carraway HE, Gojo I, DeZern A, Gore SD. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher‐risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. British Journal Of Haematology 2016, 176: 241-247. PMID: 27790720, DOI: 10.1111/bjh.14407.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeHigh-dose lenalidomideAcute myeloid leukemiaOverall survivalTrilineage dysplasiaMyelodysplastic syndromeMyeloid leukemiaNeutropenic fever/infectionInternational Working Group criteriaChemotherapy-ineligible patientsDoses of lenalidomideFever/infectionPoor-risk karyotypeRobust clinical activityMedian overall survivalPhase 2 trialPhase II trialKaplan-Meier methodElderly AMLII trialPrimary endpointFrontline therapyDosing schedulesGroup criteriaLimited therapies
2015
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine
Zeidan AM, Ali N, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clinical Lymphoma Myeloma & Leukemia 2015, 15: 705-710. PMID: 26440749, DOI: 10.1016/j.clml.2015.08.083.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesFirst-line therapyErythropoiesis-stimulating agentsFailure of treatmentTreatment failureInternational Working Group 2006 criteriaResponse rateSecond-line therapyMyelodysplastic syndrome patientsHigh response rateChromosome 5q deletionAzacitidine useHematologic improvementLenalidomide treatmentOverall survivalAnemic patientsMyelodysplastic syndromeSyndrome patientsLarge cohortLenalidomideAzacitidinePatientsLeukemic progressionClinical databaseTherapy
2014
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current Opinion In Hematology 2014, 21: 123-130. PMID: 24335709, PMCID: PMC4124617, DOI: 10.1097/moh.0000000000000016.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAzacitidineDNA MethylationHematopoietic Stem Cell TransplantationHumansInduction ChemotherapyLenalidomideMolecular Targeted TherapyMyelodysplastic SyndromesPrognosisRecurrenceRetreatmentThalidomideTransplantation, HomologousTreatment FailureTreatment OutcomeConceptsMyelodysplastic syndromeAllogeneic stem cell transplantationPathogenesis of MDSOnly curative modalityStem cell transplantationCombination treatment strategiesCombination therapeutic strategiesNovel therapeutic approachesHMA failureHMA therapyCurative modalityObjective responseRelapse rateDismal prognosisProlong survivalInvestigational agentsModest efficacyCell transplantationClinical trialsTreatment strategiesTherapeutic approachesTherapeutic strategiesBiologic underpinningsMost respondersMolecular pathways